[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9g7hbrrYI4yQ-4Fho-t38SukRKAnyVJr5ZLT1Or8rXQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"University College London Hospitals",[4],62,false,6,4,524598,0,54,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Prostate Cancer",10,{"name":18,"count":19},"Tinnitus",3,{"name":21,"count":19},"Breast Cancer",{"name":23,"count":24},"Epilepsy",2,{"name":26,"count":24},"Colorectal Cancer",{"name":28,"count":24},"Critical Illness",{"name":30,"count":24},"Lung Cancer",{"name":32,"count":24},"Sexual Dysfunction",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,68,96,114,139,179,204,222,240,258,276,302,327],{"intervention":43,"totalTrials":44,"cells":45},"Pegylated interferon-alfa2a (Pegasys); ribavirin",1,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":66},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT00152581","Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication","COMPLETED",[39],"2002-04",40,[64],"Chronic Hepatitis C, HCV Genotype 1",[43],{"trials":67,"activeCount":11},[],{"intervention":69,"totalTrials":44,"cells":70},"Phenylephrine",{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":79,"NA":94},{"trials":72,"activeCount":11},[],{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[81],{"nctId":82,"briefTitle":83,"status":84,"phases":85,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":92},"NCT01243970","Ephedrine vs Phenylephrine - ECG Changes","TERMINATED",[39],"2016-01","2012-04",29,[90,91],"Spinal Anesthesia","Pregnancy",[69,93],"Ephedrine",{"trials":95,"activeCount":11},[],{"intervention":93,"totalTrials":44,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":112},{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[],{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[108],{"nctId":82,"briefTitle":83,"status":84,"phases":109,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":110,"interventions":111},[39],[90,91],[69,93],{"trials":113,"activeCount":11},[],{"intervention":115,"totalTrials":44,"cells":116},"systemic chemotherapy",{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":135,"NA":137},{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[],{"trials":124,"activeCount":11},[125],{"nctId":126,"briefTitle":127,"status":59,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT01086618","Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery",[37,38],"2013-01","2013-07","2010-01",500,[26],[115],{"trials":136,"activeCount":11},[],{"trials":138,"activeCount":11},[],{"intervention":140,"totalTrials":24,"cells":141},"carboplatin",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[],{"trials":147,"activeCount":11},[148,161],{"nctId":149,"briefTitle":150,"status":59,"phases":151,"primaryCompletion":152,"start":153,"enrollment":154,"conditions":155,"interventions":159},"NCT00321633","Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer",[37],"2009-09","2005-09",148,[156,157,21,158],"brca1 Mutation Carrier","brca2 Mutation Carrier","Hereditary Breast\u002FOvarian Cancer (brca1, brca2)",[140,160],"docetaxel",{"nctId":162,"briefTitle":163,"status":164,"phases":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT00462397","Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer","UNKNOWN",[37],"2005-06",50,[169],"Cervical Cancer",[140,171,172],"cisplatin","paclitaxel",{"trials":174,"activeCount":11},[],{"trials":176,"activeCount":11},[],{"trials":178,"activeCount":11},[],{"intervention":180,"totalTrials":44,"cells":181},"dutasteride",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":183,"activeCount":11},[],{"trials":185,"activeCount":11},[],{"trials":187,"activeCount":11},[188],{"nctId":189,"briefTitle":190,"status":164,"phases":191,"primaryCompletion":192,"start":193,"enrollment":194,"conditions":195,"interventions":196},"NCT01193855","Dutasteride in Treating Patients With Prostate Cancer",[37],"2012-01","2010-06",42,[15],[180,197],"gadolinium-chelate",{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[],{"trials":203,"activeCount":11},[],{"intervention":197,"totalTrials":44,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":207,"activeCount":11},[],{"trials":209,"activeCount":11},[],{"trials":211,"activeCount":11},[212],{"nctId":189,"briefTitle":190,"status":164,"phases":213,"primaryCompletion":192,"start":193,"enrollment":194,"conditions":214,"interventions":215},[37],[15],[180,197],{"trials":217,"activeCount":11},[],{"trials":219,"activeCount":11},[],{"trials":221,"activeCount":11},[],{"intervention":160,"totalTrials":44,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":234,"PHASE4":236,"NA":238},{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[230],{"nctId":149,"briefTitle":150,"status":59,"phases":231,"primaryCompletion":152,"start":153,"enrollment":154,"conditions":232,"interventions":233},[37],[156,157,21,158],[140,160],{"trials":235,"activeCount":11},[],{"trials":237,"activeCount":11},[],{"trials":239,"activeCount":11},[],{"intervention":171,"totalTrials":44,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":252,"PHASE4":254,"NA":256},{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[],{"trials":247,"activeCount":11},[248],{"nctId":162,"briefTitle":163,"status":164,"phases":249,"start":166,"enrollment":167,"conditions":250,"interventions":251},[37],[169],[140,171,172],{"trials":253,"activeCount":11},[],{"trials":255,"activeCount":11},[],{"trials":257,"activeCount":11},[],{"intervention":172,"totalTrials":44,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":261,"activeCount":11},[],{"trials":263,"activeCount":11},[],{"trials":265,"activeCount":11},[266],{"nctId":162,"briefTitle":163,"status":164,"phases":267,"start":166,"enrollment":167,"conditions":268,"interventions":269},[37],[169],[140,171,172],{"trials":271,"activeCount":11},[],{"trials":273,"activeCount":11},[],{"trials":275,"activeCount":11},[],{"intervention":277,"totalTrials":44,"cells":278},"Lamotrigine",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[],{"trials":284,"activeCount":11},[285],{"nctId":286,"briefTitle":287,"status":59,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT00257855","A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis",[37],"2009-01","2009-02","2005-11",120,[294],"Secondary Progressive Multiple Sclerosis",[277],{"trials":297,"activeCount":11},[],{"trials":299,"activeCount":11},[],{"trials":301,"activeCount":11},[],{"intervention":303,"totalTrials":44,"cells":304},"gene expression analysis",{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[],{"trials":312,"activeCount":11},[],{"trials":314,"activeCount":11},[],{"trials":316,"activeCount":11},[317],{"nctId":318,"briefTitle":319,"status":164,"phases":320,"primaryCompletion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT00691509","Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer",[],"2010-12","2005-01",2300,[21],[303,326],"polymorphism analysis",{"intervention":326,"totalTrials":44,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":330,"activeCount":11},[],{"trials":332,"activeCount":11},[],{"trials":334,"activeCount":11},[],{"trials":336,"activeCount":11},[],{"trials":338,"activeCount":11},[],{"trials":340,"activeCount":11},[341],{"nctId":318,"briefTitle":319,"status":164,"phases":342,"primaryCompletion":321,"start":322,"enrollment":323,"conditions":343,"interventions":344},[],[21],[303,326]]